To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Clinical trial NCT07116473 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07116473
Sponsor: Eidos Therapeutics, a BridgeBio company
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Amyloidosis in Transthyretin (TTR)Amyloidosis, Familial Amyloid Cardiomyopathy Amyloid Cardiomyopathy, Transthyretin-Related Amyloidogenic Transthyretin (ATTR) Amyloidosis Heart Disease Cardiomyopathies Amyloidosis, Hereditary, Transthyretin-Related Polyneuropathies Amyloidosis

Start date: 2026-11-01
Primary completion: 2037-11-01
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.